{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:36:28Z","timestamp":1793090188068,"version":"4.5.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105518","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:18:04Z","timestamp":1786022284000},"page":"105518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Inflammatory breast cancer: Improving research and care through the integration of preclinical evidence and technological advances"],"prefix":"10.1016","volume":"227","author":[{"given":"Eleonora","family":"Nicolo`","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maroua","family":"Manai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Reduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cristofanilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105518_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10549-020-05938-2","article-title":"Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database","volume":"185","author":"Abraham","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/1055-9965.EPI-15-1221","article-title":"Circulating cancer-associated macrophage-like cells differentiate malignant breast cancer and benign breast conditions","volume":"25","author":"Adams","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.critrevonc.2026.105518_bib3","article-title":"Small extracellular vesicle-encapsulated miR-181b-5p, miR-222-3p and let-7a-5p: Next generation plasma biopsy-based diagnostic biomarkers for inflammatory breast cancer","volume":"16","author":"Ahmed","year":"2021","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105518_bib4","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO5-06-02","article-title":"Abstract PO5-06-02: Phase II Trial of Combination of Atezolizumab, Cobimetinib and Eribulin (ACE) or Atezolizumab and Eribulin (AE) in patients with metastatic inflammatory breast cancer (IBC): Clinical data of both cohorts","volume":"84","author":"Alexander","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02643-y","article-title":"Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients","volume":"11","author":"Allouchery","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105518_bib6","first-page":"5079","article-title":"A novel human xenograft model of inflammatory breast cancer","volume":"59","author":"Alpaugh","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.diii.2011.12.003","article-title":"Imaging inflammatory breast cancer","volume":"93","author":"Alunni","year":"2012","journal-title":"Diagn. Interv. Imaging"},{"key":"10.1016\/j.critrevonc.2026.105518_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10616-017-0134-z","article-title":"MiR-221\/222 promote chemoresistance to cisplatin in ovarian cancer cells by targeting PTEN\/PI3K\/AKT signaling pathway","volume":"70","author":"Amini-Farsani","year":"2018","journal-title":"Cytotechnology"},{"key":"10.1016\/j.critrevonc.2026.105518_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3233\/BD-2006-22103","article-title":"Epidemiology of inflammatory breast cancer (IBC)","volume":"22","author":"Anderson","year":"2006","journal-title":"Breast Dis."},{"key":"10.1016\/j.critrevonc.2026.105518_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083113","article-title":"High Serum miR-19a Levels Are Associated with Inflammatory Breast Cancer and Are Predictive of Favorable Clinical Outcome in Patients with Metastatic HER2+ Inflammatory Breast Cancer","volume":"9","author":"Anfossi","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105518_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-018-4834-7","article-title":"The combined presence of CD20\u2009+\u2009B cells and PD-L1\u2009+\u2009tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome","volume":"171","author":"Arias-Pulido","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10552-015-0712-3","article-title":"Epidemiological risk factors associated with inflammatory breast cancer subtypes","volume":"27","author":"Atkinson","year":"2016","journal-title":"Cancer Causes & Control."},{"key":"10.1016\/j.critrevonc.2026.105518_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2024.104870","article-title":"Characterization of mammographic markers of inflammatory breast cancer (IBC)","volume":"129","author":"Barkana","year":"2025","journal-title":"Phys. Med."},{"key":"10.1016\/j.critrevonc.2026.105518_bib14","article-title":"Imaging Modalities in Inflammatory Breast Cancer (IBC) Diagnosis: A Computer-Aided Diagnosis System Using Bilateral Mammography Images","volume":"23","author":"Barkana","year":"2022","journal-title":"Sens. (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105518_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1929724","article-title":"Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors","volume":"10","author":"Bertucci","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.critrevonc.2026.105518_bib16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1470-2045(16)00011-5","article-title":"Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study","volume":"17","author":"Bertucci","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib17","doi-asserted-by":"crossref","first-page":"13506","DOI":"10.18632\/oncotarget.3642","article-title":"PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy","volume":"6","author":"Bertucci","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105518_bib18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.breast.2014.06.008","article-title":"Genomic profiling of inflammatory breast cancer: A review","volume":"23","author":"Bertucci","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2026.105518_bib19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s12967-024-05198-4","article-title":"Mutational landscape of inflammatory breast cancer","volume":"22","author":"Bertucci","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105518_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/1878-0261.12621","article-title":"NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers","volume":"14","author":"Bertucci","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-017-4176-x","article-title":"Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients","volume":"163","author":"Bingham","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminoncol.2007.11.017","article-title":"Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features","volume":"35","author":"Boussen","year":"2008","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diii.2011.12.001","article-title":"Breast inflammation: Clinical examination, aetiological pointers","volume":"93","author":"Boutet","year":"2012","journal-title":"Diagn. Interv. Imaging"},{"key":"10.1016\/j.critrevonc.2026.105518_bib24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1186\/s12967-024-05553-5","article-title":"Inflammatory breast cancer microenvironment repertoire based on DNA methylation data deconvolution reveals actionable targets to enhance the treatment efficacy","volume":"22","author":"Calanca","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105518_bib25","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1535-7163.MCT-17-0061","article-title":"Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer","volume":"16","author":"Chae","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2026.105518_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101026","article-title":"Gene expression profiles of inflammatory breast cancer reveal high heterogeneity across the epithelial-hybrid-mesenchymal spectrum","volume":"14","author":"Chakraborty","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib27","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/j.annonc.2024.08.276","article-title":"337P Is presence of molecular residual disease after pathologic complete response associated with relapse in inflammatory breast cancer?","volume":"35","author":"Chen","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib28","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1007\/s00432-016-2189-1","article-title":"Human papillomavirus E6 and E7 oncoproteins affect the expression of cancer-related microRNAs: additional evidence in HPV-induced tumorigenesis","volume":"142","author":"Chiantore","year":"2016","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114559","article-title":"Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from algeria compared with other types of breast cancer tumors","volume":"9","author":"Corbex","year":"2014","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105518_bib30","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/cncr.22927","article-title":"Inflammatory breast cancer (IBC) and patterns of recurrence","volume":"110","author":"Cristofanilli","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100220","article-title":"Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)","volume":"6","author":"Dano","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105518_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114227","article-title":"Artificial intelligence breakthroughs in pioneering early diagnosis and precision treatment of breast cancer: A multimethod study","volume":"209","author":"Darbandi","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib33","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/annonc\/mdq345","article-title":"International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment","volume":"22","author":"Dawood","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib34","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/annonc\/mdq239","article-title":"Incidence of and survival following brain metastases among women with inflammatory breast cancer","volume":"21","author":"Dawood","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib35","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/cncr.25682","article-title":"Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early","volume":"117","author":"Dawood","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib36","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ccell.2024.04.008","article-title":"Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer","volume":"42","author":"Dyikanov","year":"2024","journal-title":"Cancer Cell."},{"key":"10.1016\/j.critrevonc.2026.105518_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195932","article-title":"Clinically relevant inflammatory breast cancer patient-derived xenograft\u2013derived ex vivo model for evaluation of tumor-specific therapies","volume":"13","author":"Eckhardt","year":"2018","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105518_bib38","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1245\/s10434-015-4888-2","article-title":"Inflammatory and Non-inflammatory Breast Cancer: A Potential Role for Detection of Multiple Viral DNAs in Disease Progression","volume":"23","author":"El-Shinawi","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib39","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3390\/biom10071059","article-title":"Inflammatory Breast Carcinoma: Elevated microRNA miR-181b-5p and Reduced miR-200b-3p, miR-200c-3p, and miR-203a-3p Expression as Potential Biomarkers with Diagnostic Value","volume":"10","author":"Fahim","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.critrevonc.2026.105518_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51703-x","article-title":"Let-7 regulates cell cycle dynamics in the developing cerebral cortex and retina","volume":"9","author":"Fairchild","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105518_bib41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13148-024-01695-x","article-title":"DNA methylation profile of inflammatory breast cancer and its impact on prognosis and outcome","volume":"16","author":"Faldoni","year":"2024","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.critrevonc.2026.105518_bib42","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/cells9051164","article-title":"Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives","volume":"9","author":"Faldoni","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105518_bib43","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.3390\/cancers12102816","article-title":"Inflammatory Breast Cancer: Clinical Implications of Genomic Alterations and Mutational Profiling","volume":"12","author":"Faldoni","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105518_bib44","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.amjsurg.2017.06.005","article-title":"Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer","volume":"214","author":"Fayanju","year":"2017","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105518_bib45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13058-020-01371-x","article-title":"Immune phenotype of patients with stage IV metastatic inflammatory breast cancer","volume":"22","author":"Fernandez","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10549-015-3436-x","article-title":"Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis","volume":"152","author":"Fouad","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib47","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.it.2023.03.005","article-title":"Epigenetic liquid biopsies: a novel putative biomarker in immunology and inflammation","volume":"44","author":"Fox-Fisher","year":"2023","journal-title":"Trends Immunol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib48","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.crad.2017.11.021","article-title":"Personalised screening: is this the way forward?","volume":"73","author":"Gilbert","year":"2018","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib49","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1148\/radiol.2015142566","article-title":"Accuracy of Digital Breast Tomosynthesis for Depicting Breast Cancer Subgroups in a UK Retrospective Reading Study (TOMMY Trial)","volume":"277","author":"Gilbert","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.critrevonc.2026.105518_bib50","first-page":"290","article-title":"Breast Cancer\u2014Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Giuliano","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105518_bib51","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.3390\/ijms22168924","article-title":"Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC)","volume":"22","author":"Gong","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105518_bib52","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.clbc.2013.12.006","article-title":"Aldehyde Dehydrogenase 1 Expression in Inflammatory Breast Cancer as Measured by Immunohistochemical Staining","volume":"14","author":"Gong","year":"2014","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib53","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1148\/radiol.2233010198","article-title":"Inflammatory Breast Carcinoma: Mammographic, Ultrasonographic, Clinical, and Pathologic Findings in 142 Cases","volume":"223","author":"G\u00fcnhan-Bilgen","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.critrevonc.2026.105518_bib54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12943-019-0995-1","article-title":"Effects of exosomes on pre-metastatic niche formation in tumors","volume":"18","author":"Guo","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib55","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1158\/0008-5472.SABCS-1051","article-title":"Novel inflammatory breast cancer cell line, MDA-IBC-1 expresses and secretes WISP3, a putative tumor suppressor in inflammatory breast cancer","volume":"69","author":"Hall","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib56","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv250","article-title":"Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer","volume":"107","author":"Hall","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2026.105518_bib57","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.7314\/APJCP.2016.17.4.1801","article-title":"Circulating Cell-free miRNA Expression and its Association with Clinicopathologic Features in Inflammatory and Non-Inflammatory Breast Cancer","volume":"17","author":"Hamdi","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.critrevonc.2026.105518_bib58","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1186\/2193-1801-3-636","article-title":"miRNAs in Sera of Tunisian patients discriminate between inflammatory breast cancer and non-inflammatory breast cancer","volume":"3","author":"Hamdi","year":"2014","journal-title":"Springerplus"},{"key":"10.1016\/j.critrevonc.2026.105518_bib59","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/jnci\/dji172","article-title":"Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute","volume":"97","author":"Hance","year":"2005","journal-title":"JNCI Journal National Cancer Institute"},{"key":"10.1016\/j.critrevonc.2026.105518_bib60","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105518_bib61","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cell.2020.07.009","article-title":"Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers","volume":"182","author":"Hoshino","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.critrevonc.2026.105518_bib62","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-23-2947","article-title":"Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy","volume":"30","author":"Iwase","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib63","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12885-020-06940-z","article-title":"Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC","volume":"20","author":"Iwase","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib64","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.7150\/jca.89453","article-title":"Circulating cancer-associated macrophage-like cells and macrophage-related cytokines in obese patients with advanced breast cancer who undergo neoadjuvant chemotherapy","volume":"15","author":"Iwase","year":"2024","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib65","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10549-021-06434-x","article-title":"Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research","volume":"192","author":"Jagsi","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib66","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1158\/1078-0432.CCR-15-1603","article-title":"Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer","volume":"22","author":"Janni","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib67","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.neo.2017.03.002","article-title":"Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)","volume":"19","author":"Joglekar-Javadekar","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2026.105518_bib68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41523-017-0023-9","article-title":"Inflammatory breast cancer: a model for investigating cluster-based dissemination","volume":"3","author":"Jolly","year":"2017","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib69","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-020-1140-x","article-title":"microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy","volume":"19","author":"Kanchan","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib70","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2007-8-8-r173","article-title":"MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system","volume":"8","author":"Kapsimali","year":"2007","journal-title":"Genome Biol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib71","first-page":"35","article-title":"Molecular subtypes in patients with inflammatory breast cancer; a single center experience","volume":"20","author":"Kertmen","year":"2015","journal-title":"J. BUON"},{"key":"10.1016\/j.critrevonc.2026.105518_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e12633","article-title":"Nivolumab with chemotherapy as neoadjuvant treatment for inflammatory breast cancer","volume":"40","author":"Kwa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib73","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/ijc.28171","article-title":"miRNA expression profiling of inflammatory breast cancer identifies a 5-miRNA signature predictive of breast tumor aggressiveness","volume":"133","author":"Lerebours","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib74","doi-asserted-by":"crossref","first-page":"539","DOI":"10.5306\/wjco.v5.i3.539","article-title":"Inflammatory breast cancer clusters: A hypothesis","volume":"5","author":"Levine","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib75","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ijc.2910270507","article-title":"Studies on the role of cellular immunity and genetics in the etiology of rapidly progressing breast cancer in tunisia","volume":"27","author":"Levine","year":"1981","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib76","article-title":"Abstract P4-08-19: Biomarker analysis: Multi-omics elucidation of Cohort 1 from a phase II study of a triple combination of Atezolizumab + cobimetinib + eribulin in patients with metastatic inflammatory breast cancer","volume":"83","author":"Lim","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib77","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41568-018-0010-y","article-title":"Inflammatory breast cancer biology: the tumour microenvironment is key","volume":"18","author":"Lim","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib78","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2004.04.068","article-title":"Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy","volume":"22","author":"Low","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib79","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS24-P1-04-17","article-title":"Abstract P1-04-17: Exosomes as drivers and biomarkers of TAM recruitment and immune evasion in inflammatory breast cancer","volume":"31","author":"Lucotti","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib80","doi-asserted-by":"crossref","first-page":"131","DOI":"10.18632\/oncotarget.117","article-title":"Breast Carcinomatous Tumoral Emboli Can Result From Encircling Lymphovasculogenesis Rather Than Lymphovascular Invasion","volume":"1","author":"Mahooti","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105518_bib81","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.3390\/cells11182926","article-title":"MARCKS as a Potential Therapeutic Target in Inflammatory Breast Cancer","volume":"11","author":"Manai","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105518_bib82","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.18632\/oncotarget.14057","article-title":"MARCKS protein overexpression in inflammatory breast cancer","volume":"8","author":"Manai","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105518_bib83","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib84","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10549-017-4165-0","article-title":"Identification of frequent somatic mutations in inflammatory breast cancer","volume":"163","author":"Matsuda","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib85","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1001\/jamaoncol.2018.1436","article-title":"Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer","volume":"4","author":"Matsuda","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib86","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136851","article-title":"Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes","volume":"10","author":"McAuliffe","year":"2015","journal-title":"PLoS. One"},{"key":"10.1016\/j.critrevonc.2026.105518_bib87","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdp207","article-title":"Circulating tumor cells in metastatic inflammatory breast cancer","volume":"20","author":"Mego","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib88","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.7150\/jca.13098","article-title":"Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer","volume":"7","author":"Mego","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib89","doi-asserted-by":"crossref","first-page":"35656","DOI":"10.18632\/oncotarget.10290","article-title":"Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer","volume":"8","author":"Mego","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105518_bib90","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13058-014-0507-6","article-title":"Circulating tumor cells in newly diagnosed inflammatory breast cancer","volume":"17","author":"Mego","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.clbc.2024.03.001","article-title":"The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)","author":"Michaels","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib92","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/qjmed\/hcae195","article-title":"Multifunctional role of the tumor-associated monocytes\/macrophages in the metastatic potential of inflammatory breast cancer","volume":"117","author":"Mohamed","year":"2024","journal-title":"QJM Int. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105518_bib93","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.3390\/cancers14092292","article-title":"Paracrine IL-6 Signaling Confers Proliferation between Heterogeneous Inflammatory Breast Cancer Sub-Clones","volume":"14","author":"Morrow","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105518_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.2910220102","article-title":"Rapidly progressing breast cancer (pouss\u00e9e \u00c9volutive) in Tunisia: Studies on delayed hypersensitivity","volume":"22","author":"Mourali","year":"1978","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-9966-33-47","article-title":"AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models","volume":"33","author":"Mu","year":"2014","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib96","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10549-015-3636-4","article-title":"Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer","volume":"154","author":"Mu","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102390","article-title":"Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis","volume":"9","author":"Nader-Marta","year":"2024","journal-title":"ESMO Open."},{"key":"10.1016\/j.critrevonc.2026.105518_bib98","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s11864-023-01077-0","article-title":"Tailoring Treatment for Patients with Inflammatory Breast Cancer","volume":"24","author":"Newman","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70447","article-title":"Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025","volume":"132","author":"Nicol\u00f2","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib100","doi-asserted-by":"crossref","first-page":"S394","DOI":"10.1016\/j.annonc.2024.08.363","article-title":"415P Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer","volume":"35","author":"Nicolo","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib101","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1200\/JCO.2023.41.16_suppl.1098","article-title":"Prognostic value of tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer (BC): A focus on inflammatory BC","volume":"41","author":"Nicol\u00f2","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib102","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1101\/gad.1861409","article-title":"miR-19 is a key oncogenic component of mir-17-92","volume":"23","author":"Olive","year":"2009","journal-title":"Genes. Dev."},{"key":"10.1016\/j.critrevonc.2026.105518_bib103","doi-asserted-by":"crossref","first-page":"4694","DOI":"10.3390\/ijms24054694","article-title":"Metadherin Regulates Inflammatory Breast Cancer Invasion and Metastasis","volume":"24","author":"Ortiz-Soto","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105518_bib104","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejso.2018.05.008","article-title":"Inflammatory breast cancer-importance of breast imaging","volume":"44","author":"Papalouka","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib105","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.breast.2003.08.004","article-title":"High incidence of HER-2 positivity in inflammatory breast cancer","volume":"13","author":"Parton","year":"2004","journal-title":"Breast"},{"key":"10.1016\/j.critrevonc.2026.105518_bib106","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdw535","article-title":"Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab","volume":"28","author":"Pierga","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib107","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-14-1705","article-title":"Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data","volume":"21","author":"Pierga","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib108","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12935-018-0709-6","article-title":"Expression signatures and roles of microRNAs in inflammatory breast cancer","volume":"19","author":"Qi","year":"2019","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.critrevonc.2026.105518_bib109","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib110","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/cncr.32062","article-title":"Prevalence of germline variants in inflammatory breast cancer","volume":"125","author":"Rana","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib111","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s10549-018-4835-6","article-title":"Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer","volume":"171","author":"Reddy","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib112","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1158\/2326-6066.CIR-18-0619","article-title":"Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer","volume":"7","author":"Reddy","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib113","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.semcancer.2019.10.008","article-title":"The curious phenomenon of dual-positive circulating cells: Longtime overlooked tumor cells","volume":"60","author":"Reduzzi","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib114","series-title":"Inflammatory Breast Cancer: An Update","first-page":"207","article-title":"Immunology of Inflammatory Breast Cancer","author":"Reuben","year":"2012"},{"key":"10.1016\/j.critrevonc.2026.105518_bib115","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13118","article-title":"miR-181a negatively modulates synaptic plasticity in hippocampal cultures and its inhibition rescues memory deficits in a mouse model of Alzheimer\u2019s disease","volume":"19","author":"Rodriguez-Ortiz","year":"2020","journal-title":"Aging Cell."},{"key":"10.1016\/j.critrevonc.2026.105518_bib116","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1038\/s41467-021-27108-8","article-title":"High endogenous CCL2 expression promotes the aggressive phenotype of human inflammatory breast cancer","volume":"12","author":"Rogic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105518_bib117","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41523-021-00379-6","article-title":"Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC","volume":"8","author":"Rypens","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib118","doi-asserted-by":"crossref","unstructured":"Rypens, C., Van Berckelaer, C., Berditchevski, F., van Dam, P., Van Laere, S., 2024. Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models. pp. 77\u2013112. https:\/\/doi.org\/10.1016\/bs.ircmb.2023.10.006.","DOI":"10.1016\/bs.ircmb.2023.10.006"},{"key":"10.1016\/j.critrevonc.2026.105518_bib119","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41523-022-00496-w","article-title":"Validation and real-world clinical application of an artificial intelligence algorithm for breast cancer detection in biopsies","volume":"8","author":"Sandbank","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-010-1324-y","article-title":"Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer","volume":"129","author":"Schairer","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib121","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10549-020-05864-3","article-title":"Risk factors for inflammatory and non-inflammatory breast cancer in North Africa","volume":"184","author":"Schairer","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib122","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10549-019-05237-5","article-title":"Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa","volume":"176","author":"Schairer","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib123","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/bcr585","article-title":"Inflammatory breast cancer: Vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model","volume":"5","author":"Shirakawa","year":"2003","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib124","doi-asserted-by":"crossref","first-page":"7495","DOI":"10.1038\/s41467-022-35245-x","article-title":"Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer","volume":"13","author":"Sivakumar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105518_bib125","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1186\/s12885-018-4634-9","article-title":"Outcome of inflammatory breast cancer in Moroccan patients: clinical, molecular and pathological characteristics of 219 cases from the National Oncology Institute (INO)","volume":"18","author":"Slaoui","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101258","article-title":"Circulating tumor cells as liquid biopsy markers in cancer patients","volume":"96","author":"Smit","year":"2024","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.critrevonc.2026.105518_bib127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13000-024-01453-w","article-title":"Artificial intelligence\u2019s impact on breast cancer pathology: a literature review","volume":"19","author":"Soliman","year":"2024","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib128","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1524-4741.2009.00755.x","article-title":"High proportion of inflammatory breast cancer in the Population-based Cancer Registry of Gharbiah, Egypt","volume":"15","author":"Soliman","year":"2009","journal-title":"Breast J."},{"key":"10.1016\/j.critrevonc.2026.105518_bib129","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO2-19-03","article-title":"Abstract PO2-19-03: Phase 2 study of response-guided neoadjuvant sacituzumab govitecan in patients with localized breast cancer (NeoSTAR)","volume":"84","author":"Spring","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.CAN-22-0423","article-title":"JAK\u2013STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States","volume":"83","author":"Stevens","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib131","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1200\/EDBK_319929","article-title":"Disparities in Breast Cancer Associated With African American Identity","author":"Stringer-Reasor","year":"2021","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"10.1016\/j.critrevonc.2026.105518_bib132","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO3-20-06","article-title":"Abstract PO3-20-06: TRUDI: A phase II study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for stage III HER2-expressing Inflammatory breast cancer","volume":"84","author":"Tarantino","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib133","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/qjmed\/hcac284","article-title":"Differential Gene Expression of fresh tissue and patient-derived explants\u2019 matricellular proteins augment inflammatory breast cancer metastasis: the possible role of IL-6 and MCP-1","volume":"116","author":"Tarek","year":"2023","journal-title":"QJM Int. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105518_bib134","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41523-024-00706-7","article-title":"Circulating tumor cells in breast cancer: clinical validity and utility","volume":"10","author":"Thomas-Bonafos","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib135","doi-asserted-by":"crossref","first-page":"e345","DOI":"10.1016\/j.clbc.2023.05.011","article-title":"Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients","volume":"23","author":"Tzschaschel","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib136","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1002\/cncr.31336","article-title":"Development of CNS metastases and survival in patients with inflammatory breast cancer","volume":"124","author":"Uemura","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib137","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.7150\/jca.23969","article-title":"International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference","volume":"9","author":"Ueno","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib138","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.amjsurg.2022.11.017","article-title":"Inflammatory breast cancer and the importance of skin punch biopsy","volume":"225","author":"Valente","year":"2023","journal-title":"Am. J. Surg."},{"key":"10.1016\/j.critrevonc.2026.105518_bib139","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/CCO.0000000000000967","article-title":"Immunotherapy for inflammatory breast cancer: current evidences and future perspectives","volume":"35","author":"Valenza","year":"2023","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102598","article-title":"The immunogram of inflammatory breast cancer","volume":"119","author":"Valenza","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105518_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115097","article-title":"Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study","volume":"213","author":"Valenza","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib142","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1158\/0008-5472.CAN-17-2158","article-title":"Inflammatory Breast Cancer Promotes Development of M2 Tumor-Associated Macrophages and Cancer Mesenchymal Cells through a Complex Chemokine Network","volume":"79","author":"Valeta-Magara","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib143","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13058-019-1108-1","article-title":"Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression","volume":"21","author":"Van Berckelaer","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.101907","article-title":"XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant","volume":"43","author":"Van Berckelaer","year":"2024","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib145","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.3390\/cancers13184656","article-title":"The Evolution and Prognostic Role of Tumour-Infiltrating Lymphocytes and Peripheral Blood-Based Biomarkers in Inflammatory Breast Cancer Patients Treated with Neoadjuvant Chemotherapy","volume":"13","author":"Van Berckelaer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105518_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.111303","article-title":"Locally advanced breast cancers: the EUSOMA experience","volume":"52","author":"van Dam","year":"2026","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib147","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/sj.bjc.6605787","article-title":"Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype","volume":"103","author":"Van der Auwera","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib148","doi-asserted-by":"crossref","first-page":"7965","DOI":"10.1158\/1078-0432.CCR-04-0063","article-title":"Increased Angiogenesis and Lymphangiogenesis in Inflammatory versus Noninflammatory Breast Cancer by Real-Time Reverse Transcriptase-PCR Gene Expression Quantification","volume":"10","author":"Van der Auwera","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib149","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/cncr.25180","article-title":"Is there a role for mammary stem cells in inflammatory breast carcinoma?","volume":"116","author":"Van Laere","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib150","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-12-2549","article-title":"Uncovering the Molecular Secrets of Inflammatory Breast Cancer Biology: An Integrated Analysis of Three Distinct Affymetrix Gene Expression Datasets","volume":"19","author":"Van Laere","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105518_bib151","doi-asserted-by":"crossref","first-page":"67904","DOI":"10.18632\/oncotarget.18958","article-title":"EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105518_bib152","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn7983","article-title":"EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer","volume":"8","author":"Wang","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2026.105518_bib153","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920932674","article-title":"A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer","volume":"12","author":"Wang","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105518_bib154","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10549-015-3381-8","article-title":"Inflammatory breast cancer and development of brain metastases: risk factors and outcomes","volume":"151","author":"Warren","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib155","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1002\/cncr.34441","article-title":"Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer","volume":"128","author":"Warren","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib156","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-024-00696-6","article-title":"Performance of an AI-powered visualization software platform for precision surgery in breast cancer patients","volume":"10","author":"Weitz","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2026.105518_bib157","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1111\/tbj.14030","article-title":"Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program","volume":"26","author":"White","year":"2020","journal-title":"Breast J."},{"key":"10.1016\/j.critrevonc.2026.105518_bib158","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1023\/B:CACO.0000024222.61114.18","article-title":"Population-Based Statistics for Women Diagnosed with Inflammatory Breast Cancer (United States)","volume":"15","author":"Wingo","year":"2004","journal-title":"Cancer Causes & Control."},{"key":"10.1016\/j.critrevonc.2026.105518_bib159","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3390\/ijms21041290","article-title":"Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer","volume":"21","author":"Winn","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105518_bib160","doi-asserted-by":"crossref","first-page":"82482","DOI":"10.18632\/oncotarget.12694","article-title":"Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models","volume":"7","author":"Wolfe","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105518_bib161","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/OP.24.00274","article-title":"Current clinical utility of circulating tumor dna testing in breast cancer: a practical approach","volume":"20","author":"Xi","year":"2024","journal-title":"JCO Oncol. Pract."},{"key":"10.1016\/j.critrevonc.2026.105518_bib162","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/onc.2010.405","article-title":"The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction","volume":"30","author":"Xiao","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105518_bib163","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-007-9671-z","article-title":"Inflammatory breast cancer: PET\/CT, MRI, mammography, and sonography findings","volume":"109","author":"Yang","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2026.105518_bib164","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1158\/1078-0432.CCR-09-0951","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer","volume":"15","author":"Zhang","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:56:43Z","timestamp":1793087803000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":164,"alternative-id":["S1040842826004051"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105518","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory breast cancer: Improving research and care through the integration of preclinical evidence and technological advances","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105518"}}